---
ticker: "GS"
company_name: "The Goldman Sachs Group, Inc."
sector: "financials-investment-banking"
asset_class: "equity"
analysis_date: "2026-03-24"
analyst: "opus-4.6 / inv-AI"
version: "3.0"
previous_version: "2.0 (2026-02-26)"
rating: "SLIGHT_OVERPRICED"
rating_display: "Slight Overpriced"
conviction_level: 6
confidence_score: 6.0
confidence_level: "MEDIUM"
current_price: 835.72
fair_value:
  low: 665
  mid: 782
  high: 899
upside_to_mid: -6.5
cross_model_review:
  status: "PENDING"
  reviewer: "GPT-5.4"
report_html: "/reports/GS.html"
trigger: "Iran war (Feb 28) + FOMC hawkish (Mar 18) + FRB capital modernization (Mar 19) + 10.3% price decline"
---

# GS -- The Goldman Sachs Group, Inc.

Valuation Analysis | March 24, 2026 | Analyst: opus-4.6 | Status: Draft | v3.0 (Update)

**UPDATE from v2.0 (Feb 26, 2026):** Fair value revised from $743 to $782 (+5.3%). Rating UPGRADED from MODERATE OVERPRICED to SLIGHT OVERPRICED. Price declined $932 to $836 (-10.3%). Key changes: FRB capital-neutral Basel III Endgame (Mar 19) -- GS is a primary beneficiary with $20-30B deployable surplus; Iran war (Feb 28) boosts trading volatility but chills M&A; FOMC hawkish hold (Mar 18) keeps rates elevated. R/R dramatically improved from 0.49:1 to 1.02:1 near-term.

## IC Summary: Capital Release Catalyst Meets War Volatility -- R/R Crosses Breakeven

> Goldman's fundamental picture has shifted materially since February. The FRB's March 19 capital-neutral Basel III re-proposal is the single most significant regulatory catalyst for GS in a decade -- freeing $20-30B in deployable surplus capital, structurally reducing trading book capital charges, and enabling accelerated buybacks starting 2027. Simultaneously, the Iran war (Day 25+) has supercharged FICC and Equities trading volumes, likely boosting Q1 revenue. However, the geopolitical uncertainty and FOMC's hawkish hold have chilled M&A execution -- record IB backlogs may not fully convert in H1. At $836 (down 10.3% from $932 in Feb), the stock now sits within the confidence band at 1.92x estimated book -- still elevated, but no longer extreme. Fair value rises from $743 to $782 (+5.3%), driven primarily by capital release upside. Near-term R/R crosses breakeven at 1.02:1 -- the first time GS has offered non-negative expected value since our coverage began.

| Metric | Value |
|--------|-------|
| Current Price | $835.72 (down 10.3% from $932 in Feb) |
| Fair Value (Weighted) | $782 (was $743, +5.3%) |
| Fair Value Band | $665 - $899 (was $632 - $854) |
| Rating | SLIGHT OVERPRICED (7.0% below upper band) |
| Risk/Reward (Near-Term) | 1.02:1 NEUTRAL (was 0.49:1) |
| Risk/Reward (Long-Term) | 1.23:1 MARGINALLY FAVORABLE (was 0.40:1) |
| Expected Value | +$1.50/share near-term (was -$44.50) |
| Confidence | MEDIUM (6.0/10), Band +/-15% |

---

## 1. What Changed Since February

| Factor | February 26 | March 24 | FV Impact |
|--------|-------------|----------|-----------|
| Price | $932 | $835.72 (-10.3%) | -- |
| FRB Capital Modernization (Mar 19) | Expected but uncertain ("increasingly pricing in") | CONFIRMED: Capital-neutral Basel III. $20-30B deployable surplus. FRTB recalibration reduces trading capital charges. Implementation 2027. | +$35 |
| Iran War (Feb 28) | Pre-war | Day 25+. FICC/Equities vol surge. Client hedging flows at record. But M&A uncertainty. | +$10 |
| FOMC (Mar 18) | Rates 3.50-3.75%, 2 cuts expected | Hawkish hold. Dot plot: 1 cut in 2026. 7/19 see zero cuts. | -$5 |
| M&A Pipeline | Record backlogs, projected +11% | Backlog intact but execution uncertain. War + rates = LBO math worse. GS projects +15% M&A but timing risk elevated. | -$5 |
| Trading Environment | Peak but sustainability uncertain | War-boosted: FICC/Equities likely Q1 beat from vol spike. But sustainability now even more uncertain -- war-driven vs organic. | +$5 |
| P/B Ratio | 2.14x (total) / 2.17x (tangible) | 1.92x (total) / 2.34x (tangible) | -- |
| **Fair Value** | **$743** | **$782 (+5.3%)** | **+$39** |
| Upside to Mid | -20.3% | -6.5% | -- |
| R/R (Near-Term) | 0.49:1 UNFAVORABLE | 1.02:1 NEUTRAL | Dramatically improved |

---

## 2. Key Metrics & Bank-Specific Data

Bank Valuation Note: Traditional EV-based metrics (EV/EBITDA, DCF-to-firm) are not applicable to banks. Debt is the raw material of the business, not optional financing. We use: P/B (primary), DDM, P/E, and Equity Cash Flow discounting. Cost of Equity replaces WACC as the discount rate.

| Metric | Value | Context |
|--------|-------|---------|
| Revenue (FY2025) | $58.28B | Record year |
| Net Income (FY2025) | $17.18B | +27% YoY |
| EPS (FY2025) | $51.32 | 2nd highest ever (after $59.45 in 2021) |
| EPS (FY2026E Consensus) | $58.64 | Would be all-time record |
| ROE (FY2025) | 15.0% | vs. 10-year avg 11-12% |
| Book Value/Share (Q4 2025 Actual) | $421.52 | Q1 2026 Est: ~$435 |
| Tangible BV/Share (Q4 2025) | $357.60 | +13.7% YoY, beat estimates by 6.4% |
| P/B (Total Book, Q1 Est.) | 1.92x | Down from 2.14x at $932. Approaching fair range. |
| P/B (Tangible Book, Q4 Actual) | 2.34x | vs. historical ~1.2x |
| P/E (Trailing) | 16.3x | 26% premium to 10-year median 12.96x (was 41%) |
| P/E (Forward FY2026E) | 14.3x | Approaching reasonable range |
| Dividend/Share | ~$20.00 | Run rate increase |
| Dividend Yield | 2.39% | Improved from 2.15% at $932 |
| Total Shareholder Yield | ~5.9% | Div (2.4%) + Buyback (~3.5%) |
| CET1 Ratio | 14.4% | vs. 11.4% req. (300bps excess). Post-Basel III: could release 150-200bps. |
| Shares Outstanding | ~296M | Declining 4-5%/year from buybacks |
| 52-Week Range | $435 - $1,035 | Currently mid-range |
| Beta | 1.35 | High for mega-cap financials |
| Analyst Consensus | ~$845-960 | Stock roughly at consensus low end |
| #1 M&A Advisor | 36.4% market share | $1.66T volume in FY2025 |

### Revenue Mix & Segment Breakdown (FY2025)

| Segment | Revenue | % of Total | Commentary |
|---------|---------|-----------|------------|
| FICC Trading | $14.5B | 25% | War vol likely boosts Q1 2026 |
| Equities Trading | $16.5B | 28% | Record. Client hedging flows elevated. |
| Investment Banking | $8.2B | 14% | Record backlog but execution risk from war/rates |
| Asset & Wealth Mgmt | $17.8B | 25% | $3.5T+ AUS. Recurring fee base growing. |
| Platform Solutions | $5.6B | 8% | Winding down consumer (Apple Card to JPM) |

---

## 3. FRB Capital Modernization -- The Key Catalyst

On March 19, 2026, the Federal Reserve, OCC, and FDIC issued three interrelated proposals that comprehensively overhaul the U.S. bank capital framework. This is the single most significant regulatory development for Goldman Sachs in a decade.

### What Changed

| Component | Old Framework | New Framework (Mar 19) | GS Impact |
|-----------|--------------|----------------------|-----------|
| Basel III Endgame | +19% aggregate capital hike (2023 proposal) | Capital-neutral (0-5% aggregate impact) | Eliminates $15-25B in new capital requirements |
| FRTB (Trading Book) | Punitive charges on market-making | Recalibrated -- reduced capital charges for trading/Treasury holdings | GS/MS as trading-heavy firms are PRIMARY beneficiaries |
| Enhanced SLR | Constrained primary dealer capacity | Relaxed -- enables deeper Treasury market-making | GS can expand fixed income franchise with less capital |
| G-SIB Surcharge | Fixed methodology | Under review for potential reduction | Further capital release possible |
| Timeline | Uncertainty | Finalization Q4 2026, implementation 2027 | 12-18mo to deploy excess capital |

### Quantifying the Impact

- **Deployable surplus**: $20-30B in excess CET1 capital across the Big Six. GS share: estimated $4-6B.
- **Buyback acceleration**: $4-6B in additional buyback capacity = ~$14-20/share additional accretion over 2027-2028.
- **ROE enhancement**: Lower equity base from accelerated buybacks raises structural ROE by ~50-75bps.
- **Trading franchise**: Reduced FRTB charges mean GS can maintain deep liquidity in FICC/Equities without capital penalty. This is a structural competitive advantage vs. non-bank market-makers.
- **NPV of capital release**: At 11.6% COE, PV of accelerated buyback stream adds ~$30-40 to fair value.

### Why GS Is a Primary Beneficiary

Goldman Sachs and Morgan Stanley are the two most trading-intensive of the Big Six banks. The FRTB recalibration disproportionately benefits firms with large trading books. GS's 46% revenue from FICC + Equities makes it the single largest beneficiary of the capital-neutral pivot.

---

## 4. Iran War & Trading Environment

### Trading Revenue Dynamics

The Iran war (Day 25+) has created extraordinary trading conditions:

| Factor | Impact on GS | Duration |
|--------|-------------|----------|
| FICC volatility surge | Commodities, FX, rates desks all benefiting from client hedging | As long as war continues |
| Equities vol (VIX elevated) | Options and derivatives revenue boost | Transient |
| Client hedging flows | Record demand for risk management products | 6-12 months post-resolution |
| Energy trading | Commodities desk capturing Hormuz disruption flows | War-dependent |
| M&A execution delay | Cross-border deals paused. Backlog grows but doesn't convert. | Until geopolitical clarity |
| IPO window narrowing | Uncertainty chills new issuance | 3-6 months post-resolution |

### Net Assessment

The war is a **net positive for GS in the near term** (Q1-Q2 2026): trading revenue likely to exceed expectations from vol spike and hedging flows. However, it is a **negative for the medium term**: M&A execution delays, IPO postponements, and potential recession from energy disruption all weigh on the IB pipeline. GS's record M&A backlog ($1.66T in FY2025) is at risk of slow conversion.

---

## 5. Valuation Methods (Bank-Adapted)

Methodology: Bank-specific weights: P/B (30%), DDM (25%), P/E (25%), Equity Cash Flow (20%). No EV metrics. COE 11.7% as discount rate. COE = Risk-Free 4.25% + Beta 1.35 x ERP 5.5% = 11.68%.

| Method | Weight | Bear Case | Base Case | Bull Case | Notes |
|--------|--------|-----------|-----------|-----------|-------|
| P/B (Gordon Growth) | 30% | $631 | $835 (was $790) | $1,022 | BV $435 x 1.92x base (1.45x bear, 2.35x bull). Capital release raises justified multiple. |
| DDM (Buyback-Adj.) | 25% | $440 | $600 (was $560) | $800 | $20 div, 13% growth (up from 12% -- capital release), 5% terminal |
| P/E Comps | 25% | $520 | $855 (was $825) | $1,054 | 15x x $57 normalized (war adjusted). 10x bear, 17x bull. |
| Equity Cash Flow | 20% | $510 | $840 (was $800) | $1,250 | Total payout model, higher payout capacity from capital release. COE 11.7%. |
| **Weighted Fair Value** | **100%** | **$534** | **$782 (was $743)** | **$1,030** | Current: $836 (6.9% above base) |

Calculation: (835 x 0.30) + (600 x 0.25) + (855 x 0.25) + (840 x 0.20) = $250.50 + $150.00 + $213.75 + $168.00 = $782.25, rounded to $782.

### Fair Value Bridge: v2.0 to v3.0

| Component | FV Impact | Rationale |
|-----------|-----------|-----------|
| FRB capital modernization | +$35 | $20-30B deployable surplus, FRTB recalibration, structural ROE lift |
| Iran war trading boost | +$10 | Near-term FICC/Equities vol, client hedging flows |
| FOMC hawkish hold | -$5 | Higher-for-longer rates, LBO math worse, COE modestly higher |
| War M&A uncertainty | -$5 | Record backlog execution risk, cross-border deal pause |
| War recession risk | +$2 | Partially offset by trading upside |
| Confidence improvement | +$2 | Capital framework clarity reduces regulatory uncertainty |
| **Net Change** | **+$39** | **$743 to $782 (+5.3%)** |

---

## 6. Cost of Equity (Not WACC)

| Component | Value | Source |
|-----------|-------|--------|
| Risk-Free Rate | 4.25% | 10Y Treasury (Mar 2026, modestly higher) |
| Beta | 1.35 | 5-year monthly vs. S&P 500 |
| Equity Risk Premium | 5.5% | Damodaran 2026 estimate |
| **Cost of Equity** | **11.7%** | 4.25% + 1.35 x 5.5% = 11.68% |

Why not WACC? For banks, deposits, repo agreements, and bonds are operational inputs (raw material for lending/trading), not optional financing. Using WACC would treat $1.7T in operational liabilities as "cheap debt," artificially lowering the discount rate. Cost of equity is the correct hurdle rate.

---

## 7. Scenario Analysis

### Near-Term (12-18 Months)

| Scenario | Probability | Target | Drivers |
|----------|------------|--------|---------|
| Bull | 25% | $1,050 | Capital release catalyst, war-boosted Q1 trading, M&A supercycle resumes post-war |
| Base | 50% | $850 | Capital release partially priced, M&A moderates, trading mean-reverts from war highs |
| Bear | 25% | $600 | Recession from war/energy shock, M&A freezes, trading losses from disorderly war escalation |

### Long-Term (3-5 Years)

| Scenario | Probability | Target | Drivers |
|----------|------------|--------|---------|
| Bull | 20% | $1,300 | Alternatives $500B+ AUM, capital release fully deployed, 15%+ ROE sustained |
| Base | 45% | $950 | Cyclical normalization then recovery, structural ROE 14.5%, buyback accretion |
| Bear | 35% | $500 | Recession + AI fee compression + private credit displacement, war aftermath ROE 10-11% |

### Risk/Reward

| Component | Near-Term | Long-Term |
|-----------|-----------|-----------|
| Expected Upside | +$60.5 (Bull: 25% x $214, Base gain: 50% x $14) | +$144.1 (Bull: 20% x $464, Base: 45% x $114) |
| Expected Downside | -$59.0 (Bear: 25% x $236) | -$117.6 (Bear: 35% x $336) |
| Expected Value | +$1.50/share (+0.2%) | +$26.50/share (+3.2%) |
| R/R Ratio | 1.02:1 NEUTRAL (was 0.49:1) | 1.23:1 MARGINALLY FAVORABLE (was 0.40:1) |

---

## 8. Confidence Analysis

| Component | Score | Weight | Contribution |
|-----------|-------|--------|-------------|
| Source Agreement | 6.0 | 0.30 | 1.80 |
| Business Stability | 6.5 | 0.25 | 1.625 |
| Forecast Visibility | 5.0 | 0.25 | 1.25 |
| Qualitative Clarity | 5.5 | 0.20 | 1.10 |
| **Total** | **6.0** | | **5.775 -> 6.0** |

Level: MEDIUM | Band Width: +/-15% | Band: $665 - $782 - $899

Confidence improved from 5.5 to 6.0: FRB capital framework provides regulatory clarity (removed a key uncertainty), and price decline brings valuation closer to fundamentals. Partially offset by war-related earnings uncertainty.

---

## 9. The Capital Release ROE Bridge

This is the key analytical update for v3.0 -- how FRB capital modernization changes the structural ROE picture:

| Component | ROE Impact | Durability |
|-----------|-----------|------------|
| **10-Year Baseline** | **11.2%** | Through-cycle average |
| + Consumer exit (crystallized) | +2.0% | PERMANENT |
| + Capital efficiency (pre-release buybacks) | +1.0% | DURABLE |
| + Alternatives mix shift | +0.5% | GROWING |
| **Pre-Release Structural Floor** | **14.7%** | Was the basis for v2.0 FV |
| + FRB capital release (2027-2028) | +0.5-0.75% | STRUCTURAL -- reduced equity base + FRTB savings |
| **Post-Release Structural Floor** | **15.2-15.5%** | NEW -- justifies 1.85-2.0x P/B |
| + Peak M&A/IB backlog | +1.0% | CYCLICAL -- war uncertainty adds timing risk |
| + Record trading revenues | +1.5% | CYCLICAL -- war-boosted but unsustainable |
| + Low credit losses | +0.5% | CYCLICAL -- will reverse in downturn |
| **Current Peak ROE** | **~18.2%** | War-boosted peak, not sustainable |

Key insight: The FRB capital release raises the structural ROE floor from 14.7% to ~15.2-15.5%. This justifies a modestly higher P/B multiple (1.85-2.0x vs. 1.5-1.8x previously). Combined with the 10% price decline, the valuation gap has compressed substantially. However, the current 1.92x P/B is still near the top of the justified range -- leaving minimal margin of safety.

---

## 10. Position Recommendation

**Rating: SLIGHT OVERPRICED | Action: HOLD / ACCUMULATE ON DIPS**

The risk/reward has fundamentally changed since February. At $836, GS is no longer a clear AVOID. The combination of (1) 10% price decline, (2) FRB capital release catalyst, and (3) war-boosted near-term trading revenue has compressed the valuation gap from 25% to 6.5%. Near-term R/R crosses breakeven at 1.02:1 -- the first non-negative expected value in our coverage.

| Parameter | Value | Rationale |
|-----------|-------|-----------|
| Entry Target | $750-800 (was $700-780) | 1.7-1.85x P/B, moderate margin of safety |
| Position Size | Small position acceptable | 1-2% of portfolio. Not yet full conviction. |
| For Existing Holders | Hold at $836 | No longer a trim call. Trim only above $950. |
| Aggressive Buy | Below $700 (P/B <1.6x) | Would imply ~10% upside to FV with margin of safety |
| Time Horizon | 12-24 months for capital release catalyst | Q4 2026 finalization, 2027 implementation |

**Why not FAIRLY PRICED?** Despite improved R/R, GS still trades 6.5% above fair value with limited margin of safety. The stock is within the confidence band (below the upper bound) but above the midpoint. The war-related earnings boost is transient. Capital release, while confirmed in direction, has 12+ months of implementation uncertainty. A recession from war-related energy disruption remains a 25% probability tail risk that could send GS to $600.

**Key Monitoring Triggers:**
- Q1 2026 earnings (April 13) -- trading revenue from war vol, IB pipeline conversion
- Basel III Endgame finalization details (Q4 2026) -- exact capital relief quantum
- Iran war resolution/escalation -- M&A execution and recession probability
- Fed rate trajectory -- dot plot evolution, impact on deal activity
- Any recession indicators -- would trigger downgrade back to MODERATE OVERPRICED

---

**Disclaimer:** This analysis is for informational purposes only and does not constitute investment advice. The author has no position in GS. All data sourced from SEC filings, public earnings reports, and analyst consensus as of March 24, 2026.

**Version History:** v1.0 (Jan 23) at $979, FV $730 | v2.0 (Feb 26) at $932, FV $743 (+2%) | v3.0 (Mar 24) at $836, FV $782 (+5.3%). Rating upgraded MODERATE OVERPRICED -> SLIGHT OVERPRICED.

**Next Review Triggers:** Q1 2026 earnings (Apr 13) | Basel III finalization (Q4 2026) | Iran war resolution | Recession indicators | Trading revenue inflection

---

*This report was generated by inv-AI's valuation framework using Claude (opus-4.6) for analysis. Cross-model review: PENDING (GPT-5.4). This is NOT financial advice. See [inv-ai.com/terms](https://www.inv-ai.com/terms) for full disclaimer.*

*AI-readable version. For the styled human-readable report, see [GS.html](/reports/GS.html).*